glp-1 receptor agonist antipsychotic weight gain study Antipsychotic-Induced in Severe Mental Illness: Risk Factors and Special Considerations | Current Psychiatry Reports Efficacy and Safety of GLP-1

CagriSema submitted for FDA approval in December 2025 with expected approval in Q4 2026 or Q1 2027, meaning launch around mid-2027

Though individual needs vary, try to get 79 hours of sleep per night

Sapienza, K

An Estimated 1 in 4 Medicare Beneficiaries With Obesity or Overweight Could Be Eligible for Medicare Coverage of Wegovy, an Anti-Obesity Drug, to Reduce Heart Risk In a new analysis, KFF finds that 3.6 million people with Medicare could be eligible for coverage of Wegovy (semaglutide) now that the Food and Drug Administration has approved the use of the anti-obesity drug to reduce the risk of heart attacks and stroke in certain patients

Far more than a protective barrier, the skin is a dynamic environment constantly adapting to stress, environmental exposure, structural change, and cellular turnover

J., Lee I